Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?

Area of Science:

• Genetics and Genomics
• Molecular Biology
• Cancer Research

Background:

• The TP53 gene encodes the p53 protein, a crucial tumor suppressor involved in DNA repair, cell cycle arrest, apoptosis, and senescence.
• Alterations in TP53 frequently lead to tumor development by disrupting these critical cellular pathways.
• TP53 is the most frequently mutated gene across all cancer types.

Purpose of the Study:

• To review recent clinical applications of CRISPR/Cas9 technology for therapeutic genome editing.
• To discuss the potential of CRISPR/Cas9 for editing the TP53 gene and modulating p53 pathway genes.

Main Methods:

• Review of current literature on CRISPR/Cas9 applications in genome editing.
• Analysis of CRISPR/Cas9's efficacy in correcting single nucleotide mutations, particularly missense mutations in TP53.
• Exploration of in vitro and in vivo models demonstrating CRISPR/Cas9 capabilities.

Main Results:

• CRISPR/Cas9 technology is advancing therapeutic genome editing for various diseases, including cancer, blindness, and blood disorders.
• The system has demonstrated success in correcting single nucleotides in diverse experimental models.
• The prevalence of missense mutations in TP53 presents significant opportunities for CRISPR/Cas9-based therapeutic strategies.

Conclusions:

• CRISPR/Cas9 technology holds substantial promise for targeting and editing the TP53 gene, offering a potential therapeutic strategy for numerous cancers.
• Further development and clinical evaluation of CRISPR/Cas9 are crucial for realizing its full potential in treating TP53-related diseases.
• The precision of CRISPR/Cas9 in correcting genetic defects positions it as a key technology for future cancer therapies.